US EditionPublished • loading... • Updated
Obinutuzumab Reduces Disease Activity in Systemic Lupus Erythematosus.
Summary by Deutsches Ärzteblatt
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Great Neck/New York – The CD20 antibody obinutuzumab, developed to treat B-cell lymphomas/leukemias and recently approved for the treatment of lupus nephritis, has reduced disease activity compared to standard therapy in a Phase 3 trial in people with systemic lupus erythematosus (SLE).
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
